Table 3.

Risk factors for mortality, heart failure and recurrent ischemia among 77 patients with rheumatoid arthritis and myocardial infarction

RA characteristics at onset of MI	N (%) or mean ± SD	Mortality Hazard Ratio (95% CI)	Heart Failure† Hazard Ratio (95% CI)	Recurrent Ischemia Hazard Ratio (95% CI)
RF and/or ACPA positive	54 (70%)	1.36 (0.73, 2.54)	1.19 (0.52, 2.73)	0.96 (0.51, 1.80)
Duration of RA, years	14.0 ± 9.5	1.23** (0.92, 1.65)	1.27** (0.86, 1.88)	0.95 (0.69, 1.32)
Rheumatoid Nodules	63 (82%)	1.29 (0.56, 2.97)	1.11 (0.40, 3.07)	0.72 (0.35, 1.49)
Erosions/ destructive changes	65 (84%)	1.76 (0.71, 4.35)	1.84 (0.54, 6.30)	1.60 (0.66, 3.85)
Severe extra-articular disease	63 (82%)	1.42 (0.63, 3.20)	0.99 (0.36, 2.69)	0.98 (0.46, 2.08)
Methotrexate	17 (22%)	0.83 (0.42, 1.66)	0.93 (0.37, 2.38)	0.91 (0.43, 1.93)
Hydroxychloroquine	9 (12%)	1.75 (0.67, 4.59)	0.67 (0.15, 2.88)	0.82 (0.28, 2.37)
Other non-biologic DMARDs	10 (13%)	2.36 (0.84, 6.62)	0.45 (0.06, 3.52)	1.09 (0.40, 2.95)
Corticosteroids	25 (32%)	1.24 (0.68, 2.27)	0.75 (0.32, 1.73)	1.47 (0.79, 2.72)

RA: rheumatoid arthritis; MI: myocardial infarction; RF: rheumatoid factor; ACPA: anti-citrullinated protein antibodies; DMARD: disease modifying antirheumatic drugs MId myocardial infarctionnt. Ref 31 not neededt ischemia) were also compared

Models adjusted for age at MI, sex and year of MI

^**hazard ratio per 10 year increase in disease duration

^†among 64 patients without heart failure prior to myocardial infarction